From the Agenda

Brexit and it's impact on the pharmaceutical industry

2016-11-24 16:30:00

Aaron Barzey


Aaron Barzey’s first taste of scientific research came in 1997, where at the young age of 14 he became youngest paid intern at Imperial College London’s history and contributed to ground breaking research in tyrosine hydroxylase and its regulation of dopamine synthesis. Since graduation Aaron been working in the pharmaceutical industry, covering Medical Affairs, Pharmacovigilance, Regulatory Affairs and Compliance, in multiple countries and companies.
At GSK, Aaron was the Global Labelling lead for the orphan drug ‘ofatumumab’. He was responsible for the company core datasheets, labelling strategy, EU labelling negations and oversaw the product launch in emerging markets. The major accomplishment was leading the launch of Arzerra for the treatment of chronic lymphatic leukaemia across the EU, Australia and other countries.
In 2015 Aaron started his own regulatory consultancy, ADB Medical, providing ad-hoc support or project specific guidance to various companies. In 2016 Aaron was chosen as the pharmaceutical industry SME to discuss the possible impact of Brexit on the pharmaceutical industry, which included debating with Nigel Farage live on national television and to discuss further on live on TV with Piers Morgan and Susanna Reid.